The year 2026 has turned into a pivotal year for the biotech capital markets. Venture funding for biotech firms reached $9.1 billion in the first half of the year, the highest total since 2022, with 38 acquisitions being completed over the same period, marking the sector’s greatest M&A pace in at least seven years. Underneath that broad recovery, mRNA technology is struggling to prove its post-pandemic second act, with few equities representing the tension as effectively as Moderna Inc. (NASDAQ:MRNA).
Q1 Top-Line Surge
The stock had risen more than 170% year-to-date by the first week of July and was still up 90-100% by the third week of July. The reason for this rise begins with real, though modest, financial data. Total revenue for the first quarter of 2026 reached $389 million, up 260% year-over-year from $108 million in Q1 2025, with net product sales of $352 million, up 309%. International markets accounted for approximately 80% of top-line revenue, suggesting a shift away from domestic post-pandemic demand. At the same time, management achieved a 26% year-over-year reduction in adjusted cash costs, exhibiting increased operational discipline.
However, the GAAP net loss for the quarter came in at $1.3 billion, inflated by the $178 million Arbutus patent settlement and a reported contingent legal cost of up to $1.3 billion related to ongoing litigation, including the new CureVac lawsuit.
Oncology Pipeline vs. Regulatory Near-Term Catalysts
The oncology pipeline is where the bull case has some validity. Back in June, Moderna reported five-year Phase 2b adjuvant melanoma follow-up results at ASCO, which read relatively well, with Phase 3 interim melanoma data coming later in 2026. On the commercial side, the FDA’s renewed review of the mRNA-1010 flu vaccine has a PDUFA date of August 5, indicating a tangible near-term catalyst beyond the oncology story.
That combination of real data and real catalysts is among the reasons why Piper Sandler raised its price target to $77 from $69 on June 26, with the firm citing Moderna’s Science Day event, making it one of the most bullish targets on Wall Street. That said, the reaction from the rest of the analyst community indicates that this bullishness is not shared. Consensus ratings remain largely at Hold across almost all measured datasets. The target range is significant, with highs approaching $77 and lows in the $18-25 area, a wide spread for a company of Moderna’s size and analyst coverage depth.
Wolfe Research’s framing directly reflects the pessimism, emphasizing that the fundamental story remains the same despite the stock’s dramatic re-rating based on incremental updates rather than actual evidence. It’s worth noting that the pipeline furthest out, a lupus CAR-T program and other Horizon 2/3 assets, will not produce income until at least 2028, implying that a significant portion of the long-term bull case is still years away from being testable at all.
Insider Transactions
Institutional behavior and insider communication indicate mixed signals from smart-money managers. As per Insider Monkey’s hedge fund database, the number of hedge funds holding stakes in the company increased to 52 as of the end of Q1 2026, from 48 in the previous quarter. However, during the first quarter of 2026, Susquehanna aggressively cut its Moderna, Inc. (NASDAQ:MRNA) holding by 96.6%, dumping roughly 1.56 million shares valued at $75 million. Adding to this cautious stance, Moderna President Stephen Hoge carried out a pre-planned 10b5-1 stock sale on July 15, selling $3.6 million in shares for $67.60, a price far above recent trading levels. Although 10b5-1 sales are scheduled in advance, the sale supports the idea that insiders are cashing in at moments of high valuation.
Insider Monkey’s View
Moderna, Inc. (NASDAQ:MRNA) is at a critical crossroads between pipeline validation and cash burn. While the company’s significant year-to-date rise and the upcoming August 5 PDUFA date suggest significant operational momentum, its $1.3 billion net loss, pending litigation costs, and substantial Q1 institutional selling by funds such as Susquehanna need a careful approach. With long-term oncology revenue years away and Wall Street’s price forecasts ranging from $18 to $77, Moderna is a high-risk, catalyst-driven company rather than a core long-term compounder.
While we acknowledge the risk and potential of MRNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRNA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None.
Hedge Fund Resource Center